1.A Clinical Evaluation of Tazarotene 0.1% Gel, With and Without a High- or Mid-High-Potency Corticosteroid, in Patients with Stable Plaque Psoriasis
Lawrence Green and Wen Sadoff. J Cutan Med Surg 2002; 95-102
A total of 259 patients were enrolled and randomized to the different treatment groups. However, 30 patients dropped out before their first post-baseline evaluation, leaving 229 patients with data beyond the baseline visit, of whom 157 (61% of original enrollees) completed the study (Table II). Of the 30 patients who discontinued before their first post-baseline evaluation, the majority were from the tazarotene monotherapy group (which had three times as many patients at baseline as any of the other groups), 6 were from the tazarotene/diflorasone cream group, 3 were from the tazarotene/fluocinonide group, 2 were from the tazarotene/mometasone furoate group, and 1 was from each of the other three groups. Demographic and clinical assessments at baseline were comparable between all treatment groups, except that the number of Caucasians was significantly smaller in the tazarotene/fluocinonide group than in the tazarotene/diflorasone cream group (p = 0.02). The mean percent body surface area involvement was significantly lower in the tazarotene/betamethasone group than in the tazarotene/mometasone group (p--0.05). The values were 3.2% in the tazarotene/mometasone group 3.0% in the tazarotene monotherapy group 2.9% in the diflorasone cream, fluticasone, and fluocinonide groups; 2.7% in the tazarotene/diflorasone diacetate ointment group; and2.3 % in the tazarotene/betamethasone group.